FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313546557> ?p ?o ?g. }

• W4313546557 endingPage "e1385" @default.
• W4313546557 startingPage "e1376" @default.
• W4313546557 abstract "Background and Objectives Modified Atkins diet (MAD) has emerged as an adjuvant therapy in drug-resistant epilepsy (DRE). Most studies are in children; there is limited evidence for DRE in adults. This study aimed to investigate whether MAD along with standard drug therapy (SDT) was indeed more effective than SDT alone in reducing seizure frequency and improving psychological outcomes at 6 months in adolescents and adults with DRE (nonsurgical). Methods A prospective randomized controlled trial was conducted at tertiary care referral center in India. Persons with DRE aged 10–55 years attending outpatient epilepsy clinics between August 2015 and April 2019, who had more than 2 seizures per month despite using at least 3 appropriate antiseizure medications (ASMs) at their maximum tolerated doses and had not been on any form of diet therapy for the past 1 year, were enrolled. Patients were assessed for the eligibility and randomly assigned to receive SDT plus MAD (intervention arm) or SDT alone (control arm). The primary outcome was >50% reduction in seizure frequency, and the secondary outcomes were quality of life (QOL), behavior, adverse events, and rate of withdrawal at 6 months. Intention-to-treat analysis was performed. Results A total of 243 patients were screened for eligibility; 160 patients (80 adults and 80 adolescents) were randomized to either the intervention or control arm. Demographic and clinical characteristics in both groups were comparable at baseline. At 6 months, >50% seizure reduction was seen in 26.2% in the intervention group vs 2.5% in the control group (95% CI 13.5–33.9; p < 0.001). Improvement in QOL was 52.1 ± 17.6 in the intervention group vs 42.5 ± 16.4 in the control group (mean difference, 9.6; 95% CI 4.3 to 14.9, p < 0.001). However, behavior scores could be performed in 49 patients, and improvement was seen in the intervention vs control group (65.6 ± 7.9 vs 71.4 ± 8.1, p = 0.015) at the end of the study. One patient had weight loss; 2 patients had diarrhea. Discussion The MAD group demonstrated improvement in all aspects (reduction in seizure frequency and behavioral problems) compared with the control group at the end of the study. MAD is an effective modality in controlling seizures; further research is required to assess its efficacy in terms of biomarkers along with descriptive metabolomics studies. Trial Registration Information The clinical trial registry of India: CTRI/2015/07/006048. Classification of Evidence This study provides Class III evidence that the MAD increases the probability of seizure reduction in adolescents and adults with DRE." @default.
• W4313546557 created "2023-01-06" @default.
• W4313546557 creator A5011870578 @default.
• W4313546557 creator A5015359174 @default.
• W4313546557 creator A5015474583 @default.
• W4313546557 creator A5024816478 @default.
• W4313546557 creator A5038826897 @default.
• W4313546557 creator A5040873281 @default.
• W4313546557 creator A5061146678 @default.
• W4313546557 creator A5067901202 @default.
• W4313546557 creator A5080146104 @default.
• W4313546557 date "2023-03-28" @default.
• W4313546557 modified "2023-10-10" @default.
• W4313546557 title "Safety, Efficacy, and Tolerability of Modified Atkins Diet in Persons With Drug-Resistant Epilepsy" @default.
• W4313546557 cites W1482049071 @default.
• W4313546557 cites W1538872823 @default.
• W4313546557 cites W1920696238 @default.
• W4313546557 cites W1981448047 @default.
• W4313546557 cites W1991284229 @default.
• W4313546557 cites W2001739084 @default.
• W4313546557 cites W2002943231 @default.
• W4313546557 cites W2068796007 @default.
• W4313546557 cites W2103410254 @default.
• W4313546557 cites W2108696783 @default.
• W4313546557 cites W2121711022 @default.
• W4313546557 cites W2141546157 @default.
• W4313546557 cites W2142427008 @default.
• W4313546557 cites W2144365512 @default.
• W4313546557 cites W2152072449 @default.
• W4313546557 cites W2152529684 @default.
• W4313546557 cites W2159855162 @default.
• W4313546557 cites W2167928136 @default.
• W4313546557 cites W2194741650 @default.
• W4313546557 cites W2199214468 @default.
• W4313546557 cites W2509394812 @default.
• W4313546557 cites W2566503906 @default.
• W4313546557 cites W2608252640 @default.
• W4313546557 cites W2765775136 @default.
• W4313546557 cites W2783641782 @default.
• W4313546557 cites W2800663093 @default.
• W4313546557 cites W2808014548 @default.
• W4313546557 cites W2900384992 @default.
• W4313546557 cites W2921392944 @default.
• W4313546557 cites W2998936740 @default.
• W4313546557 cites W3046957538 @default.
• W4313546557 cites W3081163663 @default.
• W4313546557 cites W4236805817 @default.
• W4313546557 cites W4240611147 @default.
• W4313546557 doi "https://doi.org/10.1212/wnl.0000000000206776" @default.
• W4313546557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36599697" @default.
• W4313546557 hasPublicationYear "2023" @default.
• W4313546557 type Work @default.
• W4313546557 citedByCount "8" @default.
• W4313546557 countsByYear W43135465572023 @default.
• W4313546557 crossrefType "journal-article" @default.
• W4313546557 hasAuthorship W4313546557A5011870578 @default.
• W4313546557 hasAuthorship W4313546557A5015359174 @default.
• W4313546557 hasAuthorship W4313546557A5015474583 @default.
• W4313546557 hasAuthorship W4313546557A5024816478 @default.
• W4313546557 hasAuthorship W4313546557A5038826897 @default.
• W4313546557 hasAuthorship W4313546557A5040873281 @default.
• W4313546557 hasAuthorship W4313546557A5061146678 @default.
• W4313546557 hasAuthorship W4313546557A5067901202 @default.
• W4313546557 hasAuthorship W4313546557A5080146104 @default.
• W4313546557 hasBestOaLocation W43135465572 @default.
• W4313546557 hasConcept C118552586 @default.
• W4313546557 hasConcept C126322002 @default.
• W4313546557 hasConcept C159110408 @default.
• W4313546557 hasConcept C168563851 @default.
• W4313546557 hasConcept C1862650 @default.
• W4313546557 hasConcept C187212893 @default.
• W4313546557 hasConcept C197934379 @default.
• W4313546557 hasConcept C2776135927 @default.
• W4313546557 hasConcept C2778186239 @default.
• W4313546557 hasConcept C2778375690 @default.
• W4313546557 hasConcept C2779951463 @default.
• W4313546557 hasConcept C2910833928 @default.
• W4313546557 hasConcept C3020110884 @default.
• W4313546557 hasConcept C512399662 @default.
• W4313546557 hasConcept C535046627 @default.
• W4313546557 hasConcept C71924100 @default.
• W4313546557 hasConceptScore W4313546557C118552586 @default.
• W4313546557 hasConceptScore W4313546557C126322002 @default.
• W4313546557 hasConceptScore W4313546557C159110408 @default.
• W4313546557 hasConceptScore W4313546557C168563851 @default.
• W4313546557 hasConceptScore W4313546557C1862650 @default.
• W4313546557 hasConceptScore W4313546557C187212893 @default.
• W4313546557 hasConceptScore W4313546557C197934379 @default.
• W4313546557 hasConceptScore W4313546557C2776135927 @default.
• W4313546557 hasConceptScore W4313546557C2778186239 @default.
• W4313546557 hasConceptScore W4313546557C2778375690 @default.
• W4313546557 hasConceptScore W4313546557C2779951463 @default.
• W4313546557 hasConceptScore W4313546557C2910833928 @default.
• W4313546557 hasConceptScore W4313546557C3020110884 @default.
• W4313546557 hasConceptScore W4313546557C512399662 @default.
• W4313546557 hasConceptScore W4313546557C535046627 @default.
• W4313546557 hasConceptScore W4313546557C71924100 @default.
• W4313546557 hasIssue "13" @default.

• next